Article Text

AB1080 Results in the follow-up of the nursing consultation for the monitoring of rheumatologic patients treated with intravenous therapies
  1. C Nájera Herranz1,
  2. I Cánovas Olmos1,
  3. J Ivorra Cortes1,
  4. E Grau Garcia1,
  5. C Alcañiz Escandell1,
  6. K Arévalo Ruales1,
  7. I Chalmeta Verdejo1,
  8. CM Feced Olmos1,
  9. JJ Fragio Gil1,
  10. R Mazarío González1,
  11. L Gonzalez Puig1,
  12. E Sánchez Labrador1,
  13. I Martínez Cordellat1,
  14. R Negueroles Albuixech1,
  15. JE Oller Rodriguez1,
  16. FM Ortiz-Sanjuan1,
  17. E Vicens Bernabeu1,
  18. D Marín Hervás2,
  19. JA Román Ivorra1
  1. 1Rheumatology Department, HUP la Fe
  2. 2Biostatistics Unit, IIS la Fe, Valencia, Spain


Background In the management of rheumatologic patients treated with intravenous therapies, its regular monitoring is recommended in order to ensure its safety. The Nursing Consultation for monitoring rheumatologic patients treated with Intravenous Therapies (NCIT) represents a major support to patient caring for it provides patient monitoring before treatment administration and prior to rheumatologist consultation.

Objectives To analyze number and types of incidents detected in the NCIT.

Methods A cross-sectional longitudinal, observational study of data from patients followed-up in the NCIT (which was initiated in 2012) was performed. We have collected data of gender, diagnosis, drug administered, incidents detected previously to the drug administration, and if the incident was detected by telephone (one day before drug administration) or by personal interview. Biostatistical analysis with R (3.3.2.) was performed.

Results We analyzed 7809 drug infusions corresponding to 545 patients (73% women). 48.25% of patients were diagnosed with osteoporosis (OP), 30.1% rheumatoid arthritis (RA), 5.7% ankylosing spondylitis (AS), 4.2% systemic lupus erythematous (SLE), 2.9% psoriatic arthritis (PsoA) and 8.3% had other diagnosis. The intravenous therapies were antiosteoporotic drug (7.8%) and biological and immunosuppressive treatment, being the most common drugs tocilizumab (38.89%), infliximab (31.9%) and abatacept (18.05%). In the 7809 treatment infusions, 477 incidents (4.1%) were registered, 33 of them related to the antiosteoporotic therapies and the other 444 incidents (93%) occurred in the biological therapies. The 63.7% of the incidents were detected by telephone one day before drug infusion. Statistical analysis showed that SLE patients exhibit higher tendency to incidents (4.8% of incidents in the 392 treatments for SLE patients; P=0.026) than other autoimmune diseases. On the other hand, RA and AS patients have incidents detected mainly by telephone ((P=0.047 y P=0.029 respectively). We also observed a high number of incidents in the intravenous administration of TCZ (P=0.009).

Conclusions The NCIT has performed the follow-up of more than 5oo patients with only 6% of incidents, contributing to an improvement in the patients' health and in its caring. Moreover, the fact of identifying the incidents helps to reduce the number of personal consultations, avoids drug preparation in those cases where this infusion is suspended, and in summary it improves management of hospital resources.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.